Fortitude Family Office LLC Boosts Stock Position in Sanofi (NASDAQ:SNY)

Fortitude Family Office LLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 708.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 752 shares of the company’s stock after buying an additional 659 shares during the period. Fortitude Family Office LLC’s holdings in Sanofi were worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in SNY. Manning & Napier Advisors LLC purchased a new stake in Sanofi during the second quarter worth approximately $13,725,000. Mount Yale Investment Advisors LLC lifted its position in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after buying an additional 12,806 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after buying an additional 30,115 shares in the last quarter. Sei Investments Co. grew its position in shares of Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after buying an additional 47,297 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in Sanofi by 10.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock worth $14,951,000 after acquiring an additional 29,082 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNY has been the subject of several research analyst reports. Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Down 1.0 %

Sanofi stock opened at $53.83 on Wednesday. The stock has a 50 day moving average of $56.06 and a two-hundred day moving average of $51.89. Sanofi has a twelve month low of $44.05 and a twelve month high of $58.97. The stock has a market capitalization of $136.61 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 1.55 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the firm posted $2.55 EPS. As a group, research analysts expect that Sanofi will post 4.25 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.